Premium
Effect of Activation of the Epstein‐Barr Virus Genome on Expression of B Cell Differentiation Antigens of Burkitt's Lymphoma Lines
Author(s) -
Yokochi Takashi,
Inoue Yoshiko,
Iwata Hitoshi,
Miyadai Toshiaki,
Kimura Yoshinobu
Publication year - 1988
Publication title -
microbiology and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.664
H-Index - 70
eISSN - 1348-0421
pISSN - 0385-5600
DOI - 10.1111/j.1348-0421.1988.tb01457.x
Subject(s) - biology , antigen , epstein–barr virus , burkitt's lymphoma , microbiology and biotechnology , virology , virus , cell culture , cd19 , pan t antigens , b cell , raji cell , monoclonal antibody , antibody , immunology , genetics
Using anti‐human B cell monoclonal antibodies prepared against B1 (CD20), B2 (CD21), B4 (CD19), and BB‐1 (B lymphoblast antigen‐1), we compared the expression of B cell differentiation antigens on a Jijoye‐P3HR‐1 cell line family of Burkitt's lymphomas. The expression of BB‐1 and B2 antigens was faint on P3HR‐1 K cell line which is an Epstein‐Barr virus (EBV) high producer. On the other hand, B1 and B4 antigens were strongly expressed on it. It was also found that BB‐1 expression decreased on P3HR‐1 cells after activation of intracellular EBV genes by treating chemically with tumor‐promoting agent (TPA) and n ‐butyrate, or on Raji cells on superinfection with EBV. This decrease of BB‐1 was blocked by the additional treatment with retinoic acid, an inhibitor of virus replication. Dual immunofluorescence staining analysis showed that the individual cell expressing EBV‐associated antigens expressed BB‐1 antigen only marginally. The relationship between the change in phenotypes of host B cells and the activation of the EBV genome is discussed.